WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > AB Enzymes
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Webinar
Conference
MedTech
Fauna Bio | April 01, 2022
A biotechnology business pioneering comparative, computational, and translational genomics, Fauna Bio, announced collaboration with the University of Wisconsin OshKosh to speed the translation of human treatments identified via research into extreme mammal adaption. Fauna Bio's sponsorship of UW Oshkosh with $500,000 expands the University's capability for biomedical partnerships and helps promote the University as a destination for academics exploring innovative animal models and ...
Research
BigHat Biosciences, Inc. | January 12, 2022
BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with Amgen applying BigHat’s platform for multi-objective optimization of a next-generation antibody. BigHat’s antibody design platform integrates a high-speed characterization with AI/ML tech...
Industrial Impact
PRnewswire | July 05, 2023
Modern Meadow, a purpose-driven biotechnology company, is proud to announce its strategic partnership with BASF, a leading global chemical company, to embark on a collaboration to revolutionize the material industry. This strategic collaboration will bring together the cutting-edge biofabrication expertise of Modern Meadow with BASF's renowned Ultramid® Ccycled® material, paving the way for the creation of a modern, sustainable, and animal-free material of the future. ...
Sequence Bio | April 08, 2022
Sequence Bio, a Newfoundland and Labrador-based discovery biology company, announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio's proprietary discovery platform to identify novel dermatologic drug targets. Under the terms of the three year agreement, Sequence Bio will perform multi-omic analyses of samples from powered discovery cohorts across multiple dermatologic indications. LEO Pharma will leverage insi...
Article
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE